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Abstract
The clinical characteristics and outcomes of 71 patients with myco-
bacterial bacteraemia, infected with human immunodeﬁciency virus
(HIV) (n = 47) and not infected with HIV (n = 24) are described.
Mycobacterium avium complex (MAC) (54.9%) constituted the most
frequently isolated mycobacterium, followed by Mycobacterium
tuberculosis (MTB) (38.0%),Mycobacterium kansasii (4.2%), andMyco-
bacterium abscessus (2.8%). The Beijing family genotype was the
most common type in MTB, and Mycobacterium intracellulare was
the most common species in MAC. The overall mortality rate was
33.8%; it was lower in HIV-infected than in non-HIV-infected
patients. HIV-infected patients were younger, had fewer underlying
diseases and better nutritional status, and were more likely to have
MAC bacteraemia than MTB bacteraemia.
Keywords: Clinical features, HIV-infected patients, mycobacte-
rial bacteraemia, Mycobacterium avium complex, Mycobacterium
tuberculosis
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Disseminated mycobacterial infection has become an impor-
tant issue with rising AIDS prevalence, improvements in
methods of detection and culture, and increased awareness
of the corresponding causative bacteria as human pathogens
[1–6].
Although the capacity to detect mycobacteria in blood is
widely available, the importance of this procedure was only
recognized recently, with the advance of the AIDS epidemics.
Information about bacteraemia caused by Mycobacterium
tuberculosis (MTB) and non-tuberculous mycobacteria (NTM)
in human immunodeﬁciency virus (HIV)-non-infected (non-
HIV) patients is still limited. This study aimed to investigate
the clinical and microbiological characteristics of mycobacte-
rial bacteraemia in HIV-infected and non-HIV patients.
Patients with mycobacterial bacteraemia were identiﬁed,
according to recommended guidelines [7], from January 2000
to June 2008 at the mycobacteriology laboratory of National
Taiwan University Hospital, a 2000-bed teaching hospital in
Taiwan. Prior to 2000, blood specimens were inoculated on
Lowenstein–Jensen slants and Middlebrook 7H11 medium
(BBL; Becton-Dickinson Diagnostic Instrument Systems,
Sparks, MD, USA). From 2000 to 2004, they were inoculated
on Lowenstein–Jensen slants and in the ﬂuorometric BAC-
TEC system (BACTEC Mycobacterium Growth Indicator
Tube 960 system, Becton-Dickinson). After January 2005, all
blood samples tested for mycobacteria were inoculated
directly in BACTEC 9240 Myco/F Lytic bottles (Becton Dick-
inson) and incubated for 4 weeks. NTM isolates were identi-
ﬁed to the species level using conventional biochemical
methods [7]. Spoligotyping was performed with a standard-
ized protocol to identify and differentiate the MTB complex
isolates [8,9]. Molecular typing of Mycobacterium avium sub-
species was performed with ﬁve primer sets, IS900, IS901,
IS1245, DT1, and DT6, as described previously [10,11].
Treatment of NTM infections was considered appropriate
if the regimen was in accordance with the American Tho-
racic Society guidelines [1]. Improved condition was deﬁned
as subsidence of symptoms accompanied by negative culture,
and persistent disease was deﬁned as a condition that did
not ﬁt both criteria after appropriate treatment.
Among 71 patients with mycobacterial bacteraemia, 47
(66.2%) were HIV-infected (Table 1). M. avium complex
(MAC) (54.9%) and MTB (38.0%) were the two most com-
mon mycobacteria associated with bacteraemia. However,
MAC was more common than MTB in HIV-infected patients.
The patients were followed up for a mean of 234 ± 218 days
(median, 183 days) between the diagnosis and the end of
treatment or death. Information on the outcome was avail-
able for 65 patients, and the overall mortality rate was
33.8%. The mortality rate was lower in HIV-infected patients
than in non-HIV patients (27.9% vs. 50.0%; p 0.078). This
could be attributed to a younger age (39.3 ± 11.1 years vs.
54.8 ± 18.6 years; p 0.001), fewer underlying diseases, better
nutritional status (albumin level, 3.1 ± 0.6 g/dL vs. 2.75 ± 0.5
g/dL; p 0.049) and more appropriate treatment (97.7% vs.
77.3%; p 0.015) in HIV-infected patients, although the mean
CD4 count in HIV-infected patients was only 10.5 ± 12.3/lL.
Patients without HIV infection had more underlying diabe-
tes, haematological cancer, autoimmune disease, and steroid
usage. However, whether their conditions were more severe
than those of HIV-infected patients during the period of
mycobacterial bacteraemia remains unclear. Clinically, it is
more likely that a physician will perform a mycobacterial
blood culture for HIV-infected patients than for non-HIV
patients. Therefore, in patients without HIV infection, the
mycobacterial blood culture might have been obtained at a
later stage of dissemination.
The clinical manifestations of disseminated mycobacterial
infection are protean, and are easily confused with those of
other infections. Previous studies showed that 80% of patients
with disseminated NTM [6], and 72–100% of patients with dis-
seminated tuberculosis [12–14], had fever. Our study showed
that fever was the most common initial sign. HIV-infected
patients had more diarrhoea and body weight loss. An abnor-
mal chest radiograph was noted in about 70% of patients. Mili-
ary nodules were identiﬁed in only two patients, which is
consistent with previous reports [13,15] and also emphasizes
that the absence of this sign cannot reliably exclude the diag-
nosis of disseminated mycobacterial infection.
Twenty-six of the 27 non-duplicated MTB isolates were
available for spoligotype analysis, and 19 (73.1%) of the 26
isolates belonged to Beijing family genotypes (ST1). In MTB
bacteraemia, there was no difference in clinical characteris-
tics and outcomes between infections with Beijing and non-
Beijing genotypes. Thirty-eight of the 39 non-duplicated
MAC isolates were available for further typing. Among them,
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17 (44.7%) belonged to Mycobacterium intracellulare, eight
(21.1%) were MAC, and 13 (34.2%) isolates remained unclas-
siﬁed. There was no difference in clinical characteristics or
outcomes between M. intracellulare and MAC bacteraemia.
Further reﬁnement in the molecular typing technique is
required for a complete typing, given that one-third of the
MTB and MAC isolates are still unclassiﬁed.
Among the 27 patients with MTB bacteraemia, 24
received antituberculosis therapy, two were not followed up
in our hospital, and one did not receive antituberculosis
therapy. The outcomes were available for only 25 patients.
Nine patients died during treatment, and the one patient
who did not receive therapy also died. In patients with MTB
bacteraemia, there was a trend towards a lower mortality
rate among HIV-infected patients than among non-HIV
patients (16.7% vs. 53.8%; p 0.097).
Among the 39 patients with MAC bacteraemia, 33 received
appropriate medical treatment, four were lost to follow-up,
and two did not receive antimycobacterial therapy. Among
the 35 patients for whom information on outcomes was avail-
able, ten died either during treatment or without treatment.
Although the mortality rate in HIV-infected patients was
higher than in non-HIV patients with MAC bacteraemia
(33.3% vs. 0%; p 0.292), larger patient numbers would be
needed to establish the signiﬁcance of this result.
Two of the three patients with Mycobacterium kansasii bac-
teraemia received appropriate treatment, but only one of
them survived. Neither of the two patients with Mycobacte-
rium abscessus bacteraemia received appropriate therapy, and
both died.
Among HIV-infected patients, the MTB cases had higher
CD4 counts (18.4 ± 18.3 vs. 7.6 ± 8.0; p 0.145) and a lower
mortality rate (16.7% vs. 33.3%; p 0.280) than the MAC
cases, although the differences were not statistically signiﬁ-
cant. Forty-three of 47 (91.5%) patients who received highly
active antiretroviral therapy had a higher CD4 count
(11.3 ± 12.7 vs. 3.3 ± 2.7; p 0.297) and a lower mortality
rate (25.6% vs. 50.0%; p 0.308) than those who did not
receive highly active antiretroviral therapy, but the difference
was not statistically signiﬁcant.
In conclusion, the clinical characteristics of mycobacterial
bacteraemia in HIV-infected patients and patients not
infected with HIV were different. HIV-infected patients had
better outcomes, were younger, had fewer underlying dis-
eases and better nutritional status; and were also more likely
to have MAC bacteraemia than MTB bacteraemia.
TABLE 1. Comparison of clinical features and outcomes between human immunodeﬁciency virus (HIV)-infected and
non-HIV-infected patients with mycobacterial bacteraemia
Variables
Patients with mycobacterial
bacteraemia (n = 71)
Patients with HIV
infection (n = 47)
Patients without
HIV infection (n = 24) p
Age, years (mean ± SD) 44.5 ± 15.8 39.3 ± 11.1 54.8 ± 18.6 0.001
Male/female ratio 61 : 10 44 : 3 17 : 7 0.025
Mycobacterium species [no. of patients (%)] <0.001
MTB 27 (38.0) 12 (25.5) 15 (62.5)
MAC 39 (54.9) 34 (72.3) 5 (20.8)
M. kansasii 3 (4.2) 1 (2.1) 2 (8.3)
M. abscessus 2 (2.8) 0 (0.0) 2 (8.3)
Underlying disease [no. of patients (%)]
Diabetes mellitus 3 (4.2) 0 (0.0) 3 (12.5) 0.035
Solid cancer 2 (2.8) 0 (0.0) 2 (8.3) 0.111
Haematological cancer 6 (8.5) 2 (4.3) 4 (16.7) 0.040
Autoimmune disease 4 (5.6) 0 (0.0) 4 (16.7) 0.011
Receiving steroid 3 (4.2) 0 (0.0) 3 (12.5) 0.035
Presentation [no. of patients (%)]
Fever 58 (81.7) 37 (78.7) 21 (87.5) 0.521
Pulmonary symptoms 40 (56.3) 25 (53.2) 15 (62.5) 0.454
Weight loss 13 (18.3) 11 (23.4) 2 (8.3) 0.195
Diarrhoea 8 (11.3) 8 (17.0) 0 (0.0) 0.045
Lymphadenopathy 4 (5.6) 3 (6.4) 1 (4.2) 1.000
Abnormal chest radiographs 50 (70.4) 31 (66.0) 19 (79.2) 0.249
Laboratory ﬁndings
White blood cells/lL (mean ± SD) 6791 ± 6419 4330 ± 3426 11 948 ± 8085 <0.001
Neutrophils/lL (mean ± SD) 5751 ± 5878 3188 ± 2926 12 159 ± 6578 <0.001
Monocytes/lL (mean ± SD) 359 ± 392 239 ± 184 653 ± 583 0.021
Lymphocytes/lL (mean ± SD) 486 ± 704 297 ± 279 943 ± 1130 0.054
Platelets · 109/L (mean ± SD) 198.6 ± 159.8 187 ± 124 223 ± 218 0.475
AST, IU/dL (mean ± SD) 43.7 ± 39.2 49.3 ± 42.3 30.7 ± 27.8 0.084
Albumin, g/dL (mean ± SD) 3.0 ± 0.6 3.1 ± 0.6 2.75 ± 0.5 0.049
CRP, mg/L (mean ± SD) 9.6 ±5.9 9.0 ± 6.2 11.3 ± 4.8 0.253
Appropriate treatment [no. of patients (%)] 59 (83.1) 42/43 (97.7) 17/22 (77.3) 0.015
Death [no. of patients (%)] 22/65 (33.8) 12/43 (27.9) 11/22 (50.0) 0.078
Death among MTB patients 9/25 (36.0) 2/12 (16.7) 7/13 (53.8) 0.097
Death among MAC patients 10/35 (28.6) 10/30 (33.3) 0/5 (0) 0.292
SD, standard deviation; MTB, Mycobacterium tuberculosis; MAC, Mycobacterium avium complex; AST, aspartate aminotransferase; CRP, C-reactive protein.
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Abstract
A clinical Klebsiella pneumoniae isolate carrying the extended-
spectrum b-lactamase gene variants blaSHV-40, blaTEM-116 and
blaGES-7 was recovered. Cefoxitin and ceftazidime activity was
most affected by the presence of these genes and an additional
resistance to trimethoprim-sulphamethoxazole was observed.
The blaGES-7 gene was found to be inserted into a class 1 integ-
ron. These results show the emergence of novel blaTEM and
blaSHV genes in Brazil. Moreover, the presence of class 1 integ-
rons suggests a great potential for dissemination of blaGES genes
into diverse nosocomial pathogens. Indeed, the blaGES-7 gene
was originally discovered in Enterobacter cloacae in Greece and,
to our knowledge, has not been reported elsewhere.
Keywords: blaGES, blaSHV, blaTEM, class 1 integron, extended-
spectrum b-lactamase, Klebsiella pneumoniae, Latin America
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